A National, Theranostic Cyclotron Resource to Drive Fundamental and Translational Medical Science

项目总结/摘要 威斯康星大学麦迪逊分校（UW）的回旋加速器小组生产用于医疗和生物医学的放射性核素。 使用16 MeV通用电气PETtrace回旋加速器进行基础科学研究。目前，这一努力 支持由UW首席研究员（PI）领导的2.37亿美元的资助研究，另外9500万美元的项目领导 通过全国分布的用户群，估计临床服务收入每年近100万美元， 每年约120万美元的联邦奖励的内部组合。广泛的利益攸关方包括 12个UW部门的PI和30多项临床研究。核医学的近期发展 回旋加速器产生的放射性核素的应用是引人注目的，需求超过了生产能力 尽管回旋加速器集团优先考虑华盛顿大学的临床和基础研究， 需求打造自主的UW产能，日益看好单光子发射 计算机断层扫描（SPECT）和治疗诊断放射性核素，该提案将建立一个新的回旋加速器设施， 容纳一个商业30兆电子伏回旋加速器毗邻现有的医学和公共卫生学院（SMPH） 威斯康星州医学研究所（WIMR）的生物医学研究设施。这台机器将增加 在每个重要领域的能力：标准和放射性金属PET放射性核素，治疗诊断β和俄歇， 发射器，以及临床和研究应用为导向的研究。新机还将增强 现有PETtrace回旋加速器的效率，将每台机器的努力集中在其优势上，同时 支持一个新生的华盛顿大学治疗诊断学和粒子治疗研究所;魏斯曼中心和阿尔茨海默氏症 疾病研究中心的神经退行性成像试验组合; PI的临床前研究工作 在威斯康星州国家灵长类动物中心和小 动物成像和放射治疗设施;和美国能源部同位素生产 网络该设施将有助于满足与FDA批准的新型 诊断和治疗放射性药物。拟议中的设施将是现有设施的四倍多。 能力和增加能力，使几个新的同位素的需求，尖端的医疗诊断 治疗程序和研究。这些能力将支持UW SMPH和UW的努力 健康，以帮助患者与阿尔茨海默氏症和帕金森氏症，癌症，慢性疼痛，和其他条件。

PROJECT SUMMARY/ABSTRACT The Cyclotron Group at the University of Wisconsin–Madison (UW) produces radionuclides for medical and fundamental scientific investigations using a 16 MeV General Electric PETtrace cyclotron. This effort currently supports $237M of funded research led by UW principal investigators (PIs), an additional $95M in projects led by a nationally distributed user base, an estimated clinical service revenue of almost $1M per year, and its own internal portfolio of federal awards of approximately $1.2M per year. The broad base of stakeholders includes PIs in 12 UW departments and over three dozen clinical research studies. Recent growth in nuclear medicine applications of cyclotron-produced radionuclides has been dramatic, and demand exceeded production capacity on multiple occasions in 2022, despite the Cyclotron Group’s prioritization of UW clinical and basic research needs. To create independent UW production capacity of increasingly promising single photon-emitting computed tomography (SPECT) and theranostic radionuclides, this proposal will build a new cyclotron facility to house a commercial 30 MeV cyclotron adjacent to the existing School of Medicine and Public Health (SMPH) biomedical research facilities of the Wisconsin Institutes for Medical Research (WIMR). This machine will add capacity in every essential area: standard and radiometal PET radionuclides, theranostic beta and Auger- emitters, and both clinical and research application-oriented research. The new machine will also enhance the efficacy of the existing PETtrace cyclotron, focusing each machine’s efforts on its strengths and simultaneously supporting a nascent UW Institute for Theranostics and Particle Therapy; the Waisman Center’s and Alzheimer’s Disease Research Center’s portfolio of neurodegenerative imaging trials; the preclinical research of PIs working on stem cell, genetic, and viral therapy development in the Wisconsin National Primate Center and the Small Animal Imaging and Radiotherapy Facility; and the United States Department of Energy Isotope Production Network. The facility will contribute to meeting projected growth associated with FDA approvals of novel diagnostic and therapeutic radiopharmaceuticals. The proposed facility will more than quadruple existing capacity and add capability to make several new isotopes that are in demand for cutting edge medical diagnostic and therapeutic procedures and research. These capabilities will support the efforts of the UW SMPH and UW Health to help patients with Alzheimer’s and Parkinson’s disease, cancer, chronic pain, and other conditions.